MA35749B1 - Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc - Google Patents

Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc

Info

Publication number
MA35749B1
MA35749B1 MA37157A MA37157A MA35749B1 MA 35749 B1 MA35749 B1 MA 35749B1 MA 37157 A MA37157 A MA 37157A MA 37157 A MA37157 A MA 37157A MA 35749 B1 MA35749 B1 MA 35749B1
Authority
MA
Morocco
Prior art keywords
vhc
arn
azido
replication
inhibitors
Prior art date
Application number
MA37157A
Other languages
English (en)
Inventor
Mark Smith
Francisco Xavier Talamas
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35749B1 publication Critical patent/MA35749B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de dérivés nucléosidiques de formule (i), où les symboles sont tels que dans la description, et des sels pharmaceutiquement acceptables de ceux-ci, et des compositions pharmaceutiques contenant de tels composés.
MA37157A 2011-12-20 2014-06-25 Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc MA35749B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577712P 2011-12-20 2011-12-20
PCT/EP2012/075688 WO2013092447A1 (fr) 2011-12-20 2012-12-17 Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc

Publications (1)

Publication Number Publication Date
MA35749B1 true MA35749B1 (fr) 2014-12-01

Family

ID=47469968

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37157A MA35749B1 (fr) 2011-12-20 2014-06-25 Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc

Country Status (31)

Country Link
US (1) US9708357B2 (fr)
EP (1) EP2794628B1 (fr)
JP (1) JP6118336B2 (fr)
KR (1) KR101687084B1 (fr)
CN (2) CN108409820A (fr)
AU (1) AU2012357986B2 (fr)
BR (1) BR112014015066A2 (fr)
CA (1) CA2869317C (fr)
CL (1) CL2014001599A1 (fr)
CO (1) CO6990719A2 (fr)
CR (1) CR20140255A (fr)
CY (1) CY1119015T1 (fr)
DK (1) DK2794628T3 (fr)
EA (1) EA024847B1 (fr)
ES (1) ES2626484T3 (fr)
HK (1) HK1200835A1 (fr)
HU (1) HUE033332T2 (fr)
IL (1) IL232843B (fr)
IN (1) IN2014CN04530A (fr)
LT (1) LT2794628T (fr)
MA (1) MA35749B1 (fr)
MX (1) MX350810B (fr)
PE (1) PE20141599A1 (fr)
PH (1) PH12014501283A1 (fr)
PL (1) PL2794628T3 (fr)
PT (1) PT2794628T (fr)
SG (1) SG11201403086YA (fr)
SI (1) SI2794628T1 (fr)
UA (1) UA110428C2 (fr)
WO (1) WO2013092447A1 (fr)
ZA (1) ZA201404444B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
IN2014CN04530A (fr) 2011-12-20 2015-09-11 Hoffmann La Roche
EP2852604B1 (fr) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
WO2013177195A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (fr) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (fr) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. Nucléosides 2', 4'-pontés pour l'infection par le vhc
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
WO2014137926A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
EP2970357B1 (fr) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
MX2015015781A (es) * 2013-05-16 2016-06-02 Riboscience Llc Derivados de nucleósido 4'-azido, 3'-deoxi-3'-fluoro sustituido.
EP3004130B1 (fr) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (fr) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
JPS6422823A (en) * 1987-07-17 1989-01-25 Asahi Glass Co Ltd Antiulcer agent
US5449664A (en) 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
CA2338490A1 (fr) 1998-07-27 2000-02-10 Sergio Altamura Derives de dicetoacides utilises comme inhibiteurs de polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000013708A1 (fr) 1998-09-04 2000-03-16 Viropharma Incorporated Methodes de traitement ou de prevention des infections virales et des maladies associees
BR9913935A (pt) 1998-09-25 2001-06-19 Viropharma Inc Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
CZ301802B6 (cs) 1999-03-19 2010-06-30 Vertex Pharmaceuticals Incorporated Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem
CA2389745C (fr) 1999-11-04 2010-03-23 Shire Biochem Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
WO2001085172A1 (fr) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP2363396A1 (fr) 2001-06-11 2011-09-07 Virochem Pharma Inc. Dérivés de thiophène comme agents antivirales contre des infections par flavivirus
EP1395571A1 (fr) 2001-06-11 2004-03-10 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a i flavivirus /i
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (fr) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
WO2003037893A1 (fr) 2001-11-02 2003-05-08 Glaxo Group Limited Derives d'acyl-dihydro-pyrrole utilises comme inhibiteurs du vhc
US20050043545A1 (en) 2001-11-02 2005-02-24 Gianpalol Bravi 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
DE60221875T2 (de) 2001-11-02 2007-12-20 Glaxo Group Ltd., Greenford 4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
EP1617848A2 (fr) 2003-04-25 2006-01-25 Gilead Sciences, Inc. Conjugues phosphonate anti-cancereux
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2004099241A1 (fr) 2003-05-09 2004-11-18 Boehringer Ingelheim International Gmbh Poche de liaison de l'inhibiteur de la polymerase ns5b du virus de l'hepatite c
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
EP1828145A4 (fr) 2004-12-10 2009-08-19 Univ Emory Analogues de nucleosides de cyclobutyle a substitution 2' et 3' pour le traitement des infections virales et de la proliferation cellulaire anormale
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
EP1987050A2 (fr) 2006-02-14 2008-11-05 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
EP2166016A1 (fr) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Dérivés phosphoramidate de nucléosides
BRPI1004575A2 (pt) * 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
RU2553656C2 (ru) * 2009-09-29 2015-06-20 ЯНССЕН ПРОДАКТС, Эл.Пи. Фосфорамидатные производные нуклеозидов
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
AU2011305652B2 (en) * 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012040127A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues nucléotidiques substitués
WO2012048013A2 (fr) 2010-10-06 2012-04-12 Inhibitex, Inc. Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales
IN2014CN04530A (fr) 2011-12-20 2015-09-11 Hoffmann La Roche

Also Published As

Publication number Publication date
AU2012357986A1 (en) 2014-06-19
PL2794628T3 (pl) 2017-09-29
WO2013092447A1 (fr) 2013-06-27
CL2014001599A1 (es) 2014-11-03
MX350810B (es) 2017-09-20
JP6118336B2 (ja) 2017-04-19
ZA201404444B (en) 2015-08-26
AU2012357986B2 (en) 2017-02-02
CA2869317C (fr) 2016-05-17
EA024847B1 (ru) 2016-10-31
LT2794628T (lt) 2017-07-10
PH12014501283A1 (en) 2014-09-08
NZ625844A (en) 2016-08-26
SI2794628T1 (sl) 2017-07-31
IL232843B (en) 2018-02-28
KR20140108303A (ko) 2014-09-05
DK2794628T3 (en) 2017-07-10
SG11201403086YA (en) 2014-07-30
BR112014015066A2 (pt) 2017-06-13
EA201491180A1 (ru) 2014-11-28
PT2794628T (pt) 2017-07-05
CY1119015T1 (el) 2018-01-10
HK1199037A1 (en) 2015-06-19
ES2626484T3 (es) 2017-07-25
IN2014CN04530A (fr) 2015-09-11
PE20141599A1 (es) 2014-10-30
US9708357B2 (en) 2017-07-18
CN104011060A (zh) 2014-08-27
CA2869317A1 (fr) 2013-06-27
KR101687084B1 (ko) 2016-12-15
HUE033332T2 (en) 2017-11-28
CR20140255A (es) 2014-08-20
JP2015500851A (ja) 2015-01-08
IL232843A0 (en) 2014-07-31
CO6990719A2 (es) 2014-07-10
HK1200835A1 (en) 2015-08-14
EP2794628B1 (fr) 2017-03-29
US20140369959A1 (en) 2014-12-18
CN108409820A (zh) 2018-08-17
UA110428C2 (uk) 2015-12-25
EP2794628A1 (fr) 2014-10-29
MX2014007028A (es) 2014-09-16

Similar Documents

Publication Publication Date Title
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
UY32062A (es) Inhibidores de beta-secretasa
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
MX375432B (es) Inhibidores de la replicacion de los virus de la gripe.
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MX350810B (es) Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc.
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
MA37886B1 (fr) Nouvelles pyridinones bicycliques
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
EA201100503A1 (ru) Глюкозидные производные и их применения
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes